Curriculum Vitae

****

Most Recent Position: Medical Technologist (ASCP) /Microbiologist

(SM-ASCP)

Health Policy (QA/QC) Analyst

Laboratory in NHANES CDC/National

Center for Health Statistics,

National Health and Nutrition Examination Surveys (NHANES),

Hyattsville, MD 20782

Personal Information

Janet Barletta, Ph.D.

Baltimore, MD 21231

Cell: 410-***-****

Email: acch1r@r.postjobfree.com

Education (copies of transcripts attached)

B.S. University of Arizona Microbiology

B.S. University of Arizona Medical Technology

M.S. 1981 Florida International University Health

Services Administration

Ph.D. 1993 University of Miami Microbiology,

Immunology

Post Graduate Education and Training

1980: Medical Technology Internship, Variety Childrens Hospital, Miami, FL

1991-1993: Post-doctoral. Johns Hopkins University, Microbiology

Department, Baltimore, MD

Certifications

Medical Technologist (MT-ASCP)

Specialty in Microbiology (ASCP, SM: Specialty in Microbiology)

National Licensure for Clinical Laboratory Technology (HEW) in Hematology,

Chemistry, Serology, and Immunohematology. Supervisor license in all

areas.

Employment History

3/2008- 8/2011: Medical Technologist/Microbiologist/Health Policy

Analyst

Center for Disease Control and Prevention (CDC), in the Planning

Branch for the National Health and Nutrition Examination Survey

(NHANES).

Supervisor: Suzanne Hemphill, (Northrop Grumman, Inc.

678-***-****: acch1r@r.postjobfree.com)(you may contact

Ms. Hemphill and Ms. Burt)

On-site supervisor: Vicki Burt, RN, MPH (CDC-NHANES; 301-

458-4127).

Responsibilities:

Microbiologist/Medical Technologist, QA/QC Analysis

Research of Laboratory Procedures (Molecular) and Experimental Design

of Pilot Studies:

1. Review of quality control data of all CDC laboratories

reporting results for the National Health and Nutrition

Examination Survey (NHANES) using various computer programs

and applications, including statistical and data management

software (SAS).

1. Design and evaluation of laboratory protocols and quality

control validation (which range from chemistry to molecular

applications) insuring compliance with GLP for laboratory

and public health testing.

Accomplishments:

1. Design of an automated process of QC analyses, using 2

applied SAS programs.. These 2 programs have reduced the

time of QC checks from days (for large laboratory datasets)

to minutes, improved the accuracy of the entire QC process by

revealing many errors previously undetected, and converted

the entire process of manual checking, graphing, and charting

QC data to an entirely automated application.

1. Publication of data results for all Clinical Biovariation

Data (in press).

1. Evaluation of the research and QC protocols required for the

following pilot studies scheduled for 2011 and 2012:

1. a comparability study of 24-hour vs spot or timed urine

collection for sodium, potassium, chloride, and iodine

analyses;

2. a comparability study of the standard tuberculin skin

test vs an immunological-based interferon-gamma assay

(ELISPOT/T-SPOT methods) for the diagnosis of latent TB

infection;

3. a market survey and comparability study of serum vs

dried blood spot results for cardio-metabolic testing in

Community HANES (an outreach program to test participants in

their homes with rapid test/fingerstick procedures):

4. design of the QA/QC criteria for the Urine Osmolality,

Urine Flow Rate, and Albumin/Creatinine Ratio for analyses

of environmental analyte concentration in urine, kidney

function, and to monitor chronic kidney disease in the US

population.

5. Population trending analyses using statistical programs

12/2000 - 3/2008: Faculty Instructor, Department of Pathology (40

hrs/week)

University of Maryland School of Medicine, Baltimore, MD

Supervisor: Niel Constantine, PhD (Professor) 410-***-****)

(acch1r@r.postjobfree.com) (you may contact Dr.

Constantine and Dr. Edelman)

Collaborator: Daniel Edelman, Ph.D. (Facility Head, NIH,

Frederick, MD)

301-***-****; acch1r@r.postjobfree.com

Responsibilities:

Microbiologist/Faculty Instructor:

Research, Development, and Optimization of New Assays for

Microbiological and Molecular Diagnoses:

1. Develop, test, and validate new assays and instruments

(rapid real-time thermocyclers, automated DNA extractors

and magnetic bead-washers) to improve sensitivity,

specificity, and rapidity of clinical testing for

unculturable viruses/pathogens and toxins.

2. Optimization and validation of the ELISA and PCR/rt-PCR

components of the assay. Specifically, we performed

research, development, and optimization of a novel

quantitative immuno-PCR assay for the detection of HIV-1

p24 antigen, pathologic prion in scrapie-infected hamster

brain homogenates, and toxic chemical agents (i.e., Ricin

and C. botulinum toxin) used in biowarfare.

Accomplishments:

1. Our laboratory was the first to show that the qIPCR test

for HIV-1 would detect infected samples within the first

10 days of HIV-1 infection (Barletta et al., Am J Clin

Pathol, 2004). We also used our qIPCR method to

demonstrate detection of the lowest reported levels of

prion protein (1 fg/mL) from scrapie infected hamster

brain homogenates (Barletta et al., J Virol Meth, 2005).

2. Further research on the original project involved

development and validation of an automated process

using magnetic beads and gold nanoparticles for the

immuno-qPCR assay. Our laboratory was the first to use

magnetic beads as the solid format in qIPCR

nanoparticle immunoassays for detection of HIV-1 and

Ricin (Barletta et al., J Virol Meth, 2009). These

studies resulted in the publication of 3 Review

articles on use of qIPCR in diagnostic detection

(Barletta J. Review: Applications of real-time immuno-

polymerase chain reaction (rt-IPCR) for the rapid

diagnoses of viral antigens and pathologic proteins.

Molecular Aspects of Medicine. 27(2-3):224-253, 2006;

Barletta J. Review: Exactly how many! Real-time

quantitative polymerase chain reaction (qPCR).

Pharmaceutical Microbiology Forum. Vol. 13 (3):2-13,

2007 and, Barletta J. Review: Immuno-PCR (IPCR) as a

unique molecular tool for detection of infectious

agents. Expert Opinion Med Diagn. 1(2):267-288, 2007).

3. A third project involved the development, optimization,

and validation of a bacteriophage plaque assay

validation studies using melting curve analyses of

heterozygous DNA products resulting in one publication

and a patent application (Edelman and Barletta, 2003).

4. As faculty, I participated in writing grant

applications and papers describing our research,

training laboratory personnel, participating in journal

clubs and seminars, and teaching the Virology

Laboratory for medical students.

While acting as Faculty for the Department of Pathology,

I designed and taught part of the

lesson material for the Medical School Virology

Laboratory under the guidance

of Roberta Kamin-Lewis PhD 410-***-****).

acch1r@r.postjobfree.com. (you may contact Dr. Kamin-

Lewis)

6/1996 -6/2000: Faculty, Biology Department (both part-time and 40

hours/week)

Baltimore City Community College (Essex Campus), Baltimore, MD

Chair: Robert Resau, PhD (Chair) (443-840-

2208)(acch1r@r.postjobfree.com)

(you may contact Dr. Resau)

Present Chair: James Hershey, MS (Present Chair) (443-840-

2636)(acch1r@r.postjobfree.com)

(you may contact Dr. Hershey)

Responsibilities: Instructor for Biology 100 (for non-science

majors), Biology 101(for science majors), Microbiology/Immunology 201 and

all associated laboratories.

6/1991-6/1996: Post-Doctoral and Research Assistant (40 hrs/week)

Johns Hopkins University, Microbiology and Genetics Departments,

Baltimore, MD

Supervisors: Richard Ambinder, MD, PhD 410-***-****)

(you may contact Dr. Ambinder)

Patricia Charache, MD 410-***-****)

(you may contact Dr. Charache)

Responsibilities:

Research, Development, and Optimization of New Assays for Microbiological

and Molecular Diagnoses:

1. Research and development in the Microbiology/Molecular Genetics

Laboratory working on the development of rapid and sensitive molecular

analyses of unculturable infectious microbes and viruses. We designed

and tested DNA, RNA, and oligonucleotide probes for the detection and

study of transcriptional regulation of HIV-1, Epstein Barr virus,

Human herpesvirus Type 6, B19 parvovirus, BK and JC virus, from

clinical samples (Barletta J, 1993; Barletta et al., 1993; Kingma et

al., 1994; DiGuiseppe et al., 1995; Murray et al., 1995).

1. Another project involved the determination of 5-azacytidine effects on

the antigenic expression of Epstein Barr virus. Transcriptional

regulatory sites of the virus were characterized and virus-infected

cells were treated with 5-deoxyazacytidine in vitro to study RNA

reactivation and protein expression (Robertson et al., 1995).

1. In the Genetics Department of we developed assays for characterization

of various genetic polymorphisms of the H19 and IGF2 genes in patient

tumor and cell line samples. I tested a microarray library of

approximately 100 chemical/drug configurations to determine the

methylation effects on the gene imprinting status from frozen tissues

as well as from in vitro cultures using RT-PCR (Matsouka et al., 1996;

Barletta et al., 1997; Randhawa et al., 1998). We then analyzed,

sequenced, and categorized these chemicals/drugs according to the

degree of methylation changes observed and developed a dosimetric

treatment plan for maximal effects with minimal toxicity.

1. Part of my responsibilities included the education of other members of

the department by both technical supervision and guidance in their

assigned molecular projects, as well as involvement in educational

seminars, laboratory meetings, and journal clubs.

1. Responsible for all administrative functions of the research

laboratory including inventory and purchasing. I routinely performed

animal surgeries (catheterization of rat arteries, veins, and bladder;

monitoring blood pressure) and chemistry studies of (rodent) renal

pathology.

1. Participation in grant applications and publications.

Accomplishments:

* Development of a rapid (in situ) hybridization test for EBV which

reduced testing time from over 24 hours to 3 hours.

* Several publications from all of these research projects (Barletta J,

1993; Barletta et al., 1993; Kingma et al., 1994; DiGuiseppe et al.,

1995; Murray et al., 1995; Robertson et al., 1995; Matsouka et al.,

1996; Barletta et al., 1997; Randhawa et al., 1998).

Research Experience

Extensive: ELISA immunoassays, protein and DNA electrophoresis, Southern

and Northern blotting, HPLC, PCR, rt-PCR, Immuno-PCR using real-time

thermocyclers (iCycler, BioRad, and Geneamp, Applied Biosystems), magnetic

bead immunoassays, in situ hybridization, tissue and viral culture, viral

plaque assays, antiviral and drug cytotoxicity testing, enzymatic and

immunologic assays, phosphoimager analyses, routine microbiology, Western

blotting.

Moderate: Chromium release assay, Gel retardation assay, FACS analyses,

ribonuclease protection assay, electron microscopy, flow cytometry.

Instrumentation: Hematology (Coulter Counter), Chemistry (Hitachi,

Ektachem, Roche Cobas, Beckman Array, Chemstrip Urine analyzer),

Microbiology (Vitek, Microscan, Bactec BioMerieux).

Professional Memberships

American Society Clinical Pathologist (1977-present)

American Society of Microbiologists (ASM)

American Association of Clinical Chemistry (AACC) presented at 2011

conference

Honors and Awards

1rst place, American Dade Writing Contest, American Medical Technologist

Assoc. for

the article "Using Projectional Analysis to Meet Your Staffing Goals",

1983.

3rd place, Graduate Student Competition for oral presentation of

"Methylation of DNA as

an Antiviral Mechanism for HSV-1", ASM Regional Meeting, Orlando, FL, 1987.

3rd place, Writing Competition, MT Today. " The Mystery of Latency", 1991.

1st place, Writing Competition, MT Today. "Developing Rapid Molecular

Diagnostic

Techniques for the Clinical Laboratory". 1992.

Resident's Award. ASCP Convention, Las Vegas, NV. "Rapid Detection of EBV

EBER-1

Small Nuclear RNA in Formalin Fixed Paraffin Embedded Tissue by RNA in situ

hybridization". 1994.

Teaching Service

Microbiology 101 Laboratory: 1986-1988, University of Miami, FL (8 hrs/wk)

Biology 101 and Laboratory: 1994-1998, Essex Community College (16 hrs/wk)

Microbiology 201 and Laboratory: 1994-1998, Essex Community College (16

hrs/wk)

Biology (non-majors): 1994-1998, Essex Community College (8 hrs/wk)

Virology Laboratory: 2000-2005, University of Maryland (4 hrs/wk)

Publications

1. Barletta, J. Using projectional analysis to reach your staffing

goals. MLO Med Lab Obs. 16(3):81-2,85,88-90, 1984.

1. Barletta, J. & Greer, S.B. Methylation of HSV-1 DNA as a mechanism

of viral inhibition:studies of an analogue of methyldeoxycytidine:

trifluoromethyldeoxycytidine (F3mdC). Antiviral Research.18:1-25,

1992.

1. Barletta, J. The mystery of latency. MT Today. May 1992:4-8.

1. Barletta, J. Developing rapid molecular diagnostic techniques for

the clinical laboratory. MT Today. 3(5):12-16, 1993.

1. Barletta, J., Kingma, D.W., Ling, Y., Charache, P., Mann, R. &

Ambinder, R.F. Rapid in situ hybridization for the diagnosis of

latent Epstein-Barr virus infection. Molecular and Cell Probes

7:105-109, 1993.

1. Kingma, D.W., Medeiros, L.J., Barletta, J., Raffeld, M., Mann,

R.B., Ambinder, R.F. & Jaffe, E.S. Epstein-Barr virus is

infrequently identified in non-Hodgkin's lymphomas associated with

Hodgkin's disease. American Journal of Surgical Pathology 18(1):48-

61, 1994.

2. DiGuiseppe, J.A., We, T.C., Zehnbauer, B.A., McDowell, P.R.,

Barletta, J.M., Ambinder, R.F. & Mann, R. Epstein-Barr virus and

progression of non-Hodgkin's lymphoma to Ki-1-positive, anaplastic

large cell phenotypes. Modern Pathology 8(5):553-559, 1995.

8.

Murray,P.G.,Deacon,E.,Young,L.S.,Barletta,J.M.,Mann,R.B.,Ambinder,R.F

.,Rowlands,B.M.,Jones, E.L., Ramsay,A.D.,and Crocker,J.

Localization of Epstein-Barr virus in Castleman's disease by in

situ hybridization and immunochemistry. Hematologic Pathology

((1),17-26,1995.

9. Robertson, K.D., Barletta, J., Samid, D. & Ambinder, R. F.

Pharmacologic activation of expression of immunodominant viral

antigens: a new strategy for the treatment of Epstein-Barr virus

associated malignancies. Current Topics in Microbiology and

Immunology 194;145-154, 1995.

10. Matsouka, S., Thompson, J., Edwards, M.C., Barletta, J.M., Grundy,

P., Kalikin, L.M., Harper,J. W., Elledge, S.J., & Feinberg, A.P.

Imprinting of the gene encoding a human cyclin-dependent kinase

inhibitor, p57 kip2, on chromosome 11p15. Proceedings of the

National Academy of Science, 93:3026-2020, 1996.

11. Barletta, J.M., Rainer, S, & Feinberg, A.P. Reversal of Loss of

Imprinting in Tumor Cells by 5-aza-2'-deoxycytidine. Cancer

Research 57:48-50, 1997.

12. Randhawa,G.S., Cui, H., Barletta, J.M., Strichman-Almashanu, L.XZ,

Talpaz, M., Kantarjian, H., Deisseroth, A.B., Champlin, R.C.,

Feinberg, AP. Loss of imprinting in disease progression in

chronic myelogenous leukemia. Blood. 91(9):3144-3147, 1998.

12. Edelman, D.C. and Barletta, J. Real-time PCR provides improved

detection and titer determinations of bacteriophage.

Biotechniques. 35(2):368-375, 2003.

12. Barletta J.M., Edelman D.C., Constantine N.T. Lowering the

detection limits of HIV-1 viral load using real-time immuno-PCR for

HIV-1 p24 antigen. Amer J Clin Pathol. 122(1): 20-27., 2004.

12. Barletta J.M., Edelman D.C., Highsmith W.E., Constantine N.T.

Detection of ultra-low levels of pathologic prion protein in

scrapie infected hamster brain homogenates using real-time immuno-

PCR. J Virol Meth. 127(2):154-164, 2005.

12. Barletta J. Review: Applications of real-time immuno-

polymerase chain reaction (rt-IPCR) for the rapid diagnoses of

viral antigens and pathologic proteins. Molecular Aspects of

Medicine. 27(2-3):224-253, 2006.

13. Barletta J. Review: Exactly how many! Real-time

quantitative polymerase chain reaction (qPCR). Pharmaceutical

Microbiology Forum. Vol. 13 (3):2-13, 2007.

12. Barletta J. Review: Immuno-PCR (IPCR) as a unique molecular

tool for detection of infectious agents. Expert Opinion Med

Diagn. 1(2):267-288, 2007.

12. Barletta J, Bartolome A, Constantine NT. Immunomagnetic

quantitative immuno-PCR for detection of less than one HIV-1

virion. J of Virological Methods. 157(2):122-132, 2009.

12. Lute S, Wang H, Sanchez D, Barletta J, Chen Qi, Brorson K.

Multiplex RT Q-PCR assay for simultaneous quantification of

three viruses used for validation of virus clearance by

biopharmaceutical production. Biologicals 37:331-337, 2009.

12. Barletta J, Hughes JP, Lacher DA. Biological variation of

hematology analytes based on the 2000-2002 National Health and

Nutrition Examination Survey (NHANES 2000-2002). National

Health Statistics Reports. Number 54, July 12, 2012.

Book Chapters

1) 1. Ryon, J.J., Zhang, J., Barletta, J.M., MacMahon, E.M.E., Ling, Y.,

Hayward, S.D., Charache, P., Mann, R.B. & Ambinder, R.F. Detection of

Epstein-Barr virus transcripts in clinical specimens in Tursz, T.,

Pagano, J.S., Ablashi, D.V., de The, G., Lenoir, G. & Pearson, G.R.

(eds): The Epstein-Barr Virus and Associated Diseases. 1993, Vol. 225,

pp. 425-432.

2) 2. Ambinder, R.F., Tsai, S.-T. & Barletta, J. The EBERs in

"Nasopharyngeal Carcinoma". Griffin, B.E. (ed.) 1994.

Abstracts

1. Barletta, J and Greer S. Methylation of HSV-1 DNA as a mechanism of

viral inhibition: studies of an analogue of methyldeoxycytidine:

trifluoromethyldeoxycytidine (F3mdCyd). International Herpesvirus

Workshop, Washington, DC, 1991.

2. Ambinder RF, Mann RB, Barletta JM, Murray P, Shapiro RS, Ling Y,

Filipovich AH. Association of Epstein-Barr Virus (EBV) with Hodgkin's

disease (HD) in patients with primary immunodeficiency and frequent

detection of EBV in lymphoid tissue without neoplastic involvement in

Wiskott-Aldrich syndrome (WAS): A survey of EBV in archival tissues from

the immunodeficiency cancer registry (ICR), American Society of

Hematology 34th annual mtg., Anaheim, CA, 1992. Blood 80 Suppl.

1:118a,1992.

3. Kingma DW, Barletta J, Medeiros LJ, Ling Y, Zarate-Osorno A, Raffeld M,

Charache P, Ambinder RF, Jaffe ES. Epstein-Barr Virus (EBV) in non-

Hodgkin's lymphomas associated with Hodgkin's disease. American Society

of Hematology 34th annual mtg., Anaheim, CA, 1992. Blood 80 Suppl.

1;118a, 1992.

4. Zarate-Osorno A, Medeiros LJ, Kingma DW, Barletta JM, Longo DL, Ambinder

RF, Jaffe ES. Non-Hodkin's lymphoma (NHL) following Hodgkin's disease

(HD). International Academy of Pathology, 1993.

5. Barletta JM, Ryon JJ, Park S, Charache P, Ambinder RF. Epstein-Barr

Virus (EBV) detection by flow cytometry in infected cells. American

Society of Microbiology, 93rd general meeting, Atlanta, GA, 1993.

6. Ambinder RF, Johnson JF, O'Conor G, Barletta JM, Bhatia K, Ahmed M,

Shanta V, Chen C, Murray P, Magrath IT. Strong Association of Epstein-

Barr Virus (EBV) with childhood Hodgkin's disease (HD) in Pakistan and

India. American society of Clinical Oncology Annual Meeting, 1993.

7. Ambinder RF, Ragni, MV, Barletta J, Bass D, Duerstein S, Mann RB.

Hemophilia Malignancy Study Group. Epstein-Barr Virus (EBV) association

of lymphoma in patients with hemophilia and AIDS. 35th annual meeting of

the American Society of Hematology, December 307, St. Louis, MO, 1993.

8. Constantine NT, Barletta J, Feng E, Edelman DC, Highsmith WE. Ultra-low

detection of HIV p24 antigen using immuno-PCR. XIV International AIDS

Conference, Barcelona, Spain, July 7-12, 2002.

9. Azzazy HM, Highsmith W, Barletta J, Constantine N. Development of

direct phage single chain variable fragment-polymerase chain reaction

(ScFv-PCR) assay. AACC 2003 Meeting and Clinical Lab Expo, Philadelphia,

PA, July 20-24, 2003.

10. Barletta J, Constantine NT, Feng E, Highsmith WE. Ultra-low detection

of HIV p24 in patient samples using immuno-PCR (IPCR) 8th World STI/AIDS

Contress, Punta de Este, Uruguay, December 2-5, 2003.

11. Constantine NT, Edelman D, Highsmith WE, Barletta J. Lowering the

Detection Limits of HIV-1 Viral Load Using Real-Time Immuno-PCR for

HIV-1 p24 Antigen. CDC Diagnostics Meeting. Association of Public

Laboratories, Washington D.C., February 2005.

12. Constantine NT, Barletta J, Edelman D, Highsmith WE. Approaching the

Detection of One Infectious Unit of Prion Protein Using Immuno-PCR.

Association of Public Health Laboratories Infectious Disease Conference,

Orlando, FL, March 2005.

13. Barletta J, Edelman DC, Constantine NT. Lowering the Detection Limits

of HIV-1 Viral Load Using Real-Time Immuno-PCR for HIV-1 p24 Antigen.

FDA Science Forum, Washington, DC, 2005.

14. Barletta J, Edelman DC, Highsmith WE, Constantine NT. Detection of 10

Infectious Units of Pathologic Prion Protein From Scrapie Infected

Hamster Brain Homogenates Using Real-time Immuno-PCR (IPCR). FDA Science

Forum, Washington, DC, 2005.

15. Barletta J, Edelman DC, Highsmith WE, Constantine NT. Detection of 10

Infectious Units of Pathologic Prion Using Real-Time Immuno-PCR (IPCR).

PDA Viral & TSE Safety Conference. Rockville, MD, 2005.

16. Constantine N, Barletta J, Bartolome A. Detecting Less Than 1 HIV

Virion Using Immuno-PCR for p24 Antigen. 17th International AIDS

Conference. Mexico City, Mexico. 2008.

17. Barletta J. Non-dioxin like polychlorinated biphenyl body burdens in

the US population by race/ethnicity and age groups for 1999-2004

(NHANES). AACC Conference, Anaheim, CA, 2010.

18. Barletta J and Bartolome A. Assay validation for quantitative immune-

PCR (qIPCR) in the ultrasensitive detection of Ricin toxin in human and

mouse sera. AACC Conference, Anaheim, CA, 2010.

Recent Speaking Engagements:

January 2007. RMUG (Rapid Microbiology Users Group). Validation of Real-

Time Quantitative PCR (qPCR). Crystal City, VA. Material from the Review:

"Exactly how many! Real-time quantitative polymerase chain reaction

(qPCR)." Pharmaceutical Microbiology Forum. Vol. 13 (3):2-13, 2007.

Contact this candidate